Viewing Study NCT04355533


Ignite Creation Date: 2025-12-25 @ 2:40 AM
Ignite Modification Date: 2025-12-29 @ 7:10 AM
Study NCT ID: NCT04355533
Status: COMPLETED
Last Update Posted: 2023-11-18
First Post: 2020-04-17
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19
Sponsor: Assistance Publique - Hôpitaux de Paris
Organization:

Study Overview

Official Title: Seroprevalence and Antibody Profiling Against SARS-CoV2 in Children and Their Parents
Status: COMPLETED
Status Verified Date: 2023-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PED-COVID
Brief Summary: The purpose of this study is to provide data on the proportion of seroconverted children and their immune status. It will also provide insight into the number of children currently infected at each time point including healthy carriers. Investigators will provide similar data on their parents in an ancillary study.
Detailed Description: The fraction of undiagnosed but likely to transmit the virus is a critical epidemiological characteristic that modulates the epidemic potential of SARS-CoV2. To adapt the epidemy control, it is essential to study the immunoprotection of the general population. A crucial question is the study of pauci or asymptomatic subjects, and in particular children who make mild forms, because they could act as a real reservoir for the spread of the virus. The serological study is essential in this context.

The serologic test Abbott will be used to study immunoprevalence. Institut Pasteur has validated test using neutralizing Ab. CEA will used a antibodies and antigen test.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2020-A00999-30 REGISTRY ID-RCB View